Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: B

Drug products: Cisordinol Depot, Cisordinol®, Cisordinol® Depot, Cisordinol-Acutard®, Clopixol, Clopixol Depot, Clopixol-Acutard

ATC code: N05AF05

Substances: zuclopenthixol, zuclopenthixol acetate, zuclopenthixol decanoate, zuclopenthixol dihydrochloride, zuclopenthixol hydrochloride


Zuclopenthixol is an antipsychotic agent of the first generation that blocks dopamine D2-receptors. Sex differences regarding the antipsychotic effect or adverse events have not been reported.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of zuclopenthixol have been found.


No studies with a clinically relevant sex analysis regarding the antipsychotic effect of zuclopenthixol have been found.

Adverse effects

Publications reporting sex differences of zuclopenthixol regarding adverse effects were not found. However, a register based study in patients older than 65 years (179 men, 356 women) did not detect any sex difference regarding the risk of death with zuclopenthixol [1].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2019-07-20


  1. Schmedt N, Kollhorst B, Enders D, Jobski K, Krappweis J, Garbe E et al. Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study. Eur Neuropsychopharmacol. 2016;26(9):1390-1400. PubMed
  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.] länk

Authors: Carl-Olav Stiller, Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson